Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Immune System Diseases

Digestive System Diseases

Infections

Rare Diseases

Carcinoma

Prostatic Neoplasms

Recurrence

Carcinoma, Ovarian Epithelial

Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Lymphoma, Non-Hodgkin

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

Vaginal Neoplasms

Vulvar Neoplasms

Liver Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Large B-Cell, Diffuse

Sarcoma

Lymphoma, B-Cell

Burkitt Lymphoma

Testicular Neoplasms

Plasmablastic Lymphoma

Lymphoma, Large-Cell, Immunoblastic

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Vaginal Cancer

Primary Liver Cancer

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

B-cell Lymphoma

Marginal Zone Lymphoma

Diffuse Large B-Cell Lymphoma

Soft Tissue Sarcoma

Germ Cells Tumors

Fallopian Tube Cancer

Penile Cancer

Vulvar Cancer

Ovarian Germ Cell Tumor

Testicular Germ Cell Tumor

Uterine Sarcoma

Urethral Cancer

Lymphoma, Large-cell, Immunoblastic

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Aflibercept

Liver Extracts

Angiogenesis Inhibitors

Growth Inhibitors

ziv-aflibercept

William P. Tew, MD

RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.

PURPOSE: This phase I trial is studying the side effects of VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

OBJECTIVES:

Primary

* Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Secondary

* Determine the steady-state pharmacokinetics of this drug in these patients.
* Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
* Determine whether antibodies to this drug develop in these patients.
* Determine, preliminarily, the ability of repeated doses of this drug to alter tumor growth and vascular permeability in these patients.

OUTLINE: This is an open-label, multicenter, extension study.

Patients receive VEGF Trap\* IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

NOTE: \*Patients receive the same drug dose that they received in MSKCC-03137 (VGFT-ST-0202)

Patients are followed monthly for 3 months.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 3-6 months.

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Regeneron Pharmaceuticals

Anus Neoplasms

Brenner Tumor

Colorectal Neoplasms

Disease Attributes

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Anal Cancer

Ovarian Low Malignant Potential Tumor

Herbal and Botanical

Capecitabine

Antimetabolites

Cola

This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

capecitabine

radiation therapy

Charles Erlichman, MD

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy.

PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.

OBJECTIVES: I. Determine the maximum tolerated dose of oral capecitabine administered in combination with pelvic radiotherapy in patients with unresectable, residual, or locally recurrent cancer localized in the pelvis. II. Determine the tolerance of this regimen in these patients. III. Determine the preliminary evidence of therapeutic acticivity of this regimen in these patients.

OUTLINE: This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

PROJECTED ACCRUAL: A maximum of 51 patients will be accrued for this study.

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis

Alliance for Clinical Trials in Oncology

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.

PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

OBJECTIVES:

Primary

* Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Secondary

* Determine the maximum tolerated intravenous dose of this drug in these patients.
* Determine the pharmacokinetics of this drug in these patients.
* Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
* Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
* Determine whether antibodies to this drug develop in these patients.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.

Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level.

In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive VEGF Trap on a separate extension protocol.

Patients are followed at weeks 1, 3, and 7 and then at 3 months.

PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.

An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Nasopharyngeal Carcinoma

Esophageal Neoplasms

Skin Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Lung Neoplasms

Esophageal Squamous Cell Carcinoma

Laryngeal Diseases

Penile Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Esophageal Diseases

Skin Diseases

Genital Neoplasms, Male

Genital Diseases, Male

Penile Diseases

Male Urogenital Diseases

Esophageal Cancer

Laryngeal Cancer

Hypopharyngeal Cancer

Dermatologic Agents

Anti-Infective Agents

Tretinoin

Isotretinoin

Interferons

Interferon-alpha

Interferon-alfa-1b

Antiviral Agents

Immunologic Factors

recombinant interferon alfa

isotretinoin

Robert O. Dillman, MD, FACP

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of cancer cells. Combining isotretinoin and interferon may be an effective treatment for some recurrent cancers.

PURPOSE: Phase II trial to study the effectiveness of interferon alfa plus isotretinoin in treating patients with recurrent cancer.

OBJECTIVES: I. Determine the response rates to treatment with daily subcutaneous interferon alpha plus oral isotretinoin in patients with advanced squamous cell carcinomas of the following body sites: head and neck, cervix, skin, esophagus, lung, and penis. II. Determine the toxicities and side effects of this treatment.

OUTLINE: Nonrandomized study. Single-agent Chemotherapy with Biological Response Modifier Therapy. Isotretinoin, 13-CRA, NSC-329481; with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.

PROJECTED ACCRUAL: 14-50 patients per tumor category (and any other tumor location, if available) will be enrolled. If none of the first 14 patients in any tumor category responds, or if only 1/22, 2/30, 3/37, 4/44, or 5/50 respond, the treatment will be considered ineffective for that tumor type.

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS

Cancer Biotherapy Research Group

Hoag Memorial Hospital Presbyterian

Robert O. Dillman, MD

Stomach Neoplasms

Breast Neoplasms

Pancreatic Neoplasms

Cholangiocarcinoma

Melanoma

Carcinoma, Renal Cell

Small Cell Lung Carcinoma

Breast Neoplasms, Male

Pleural Effusion, Malignant

Pleural Effusion

Mesothelioma

Mesothelioma, Malignant

Thymoma

Thymus Neoplasms

Carcinoid Tumor

Trophoblastic Neoplasms

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms, Mesothelial

Pleural Neoplasms

Pleural Diseases

Stomach Cancer

Pancreatic Cancer

Bile Duct Cancer

Renal Cell Carcinoma

Small Cell Lung Cancer

Gallbladder Cancer

Breast Cancer, Male

Malignant Mesothelioma

Gestational Trophoblastic Tumor

Small Intestine Cancer

Interferon-beta

recombinant adenovirus-hIFN-beta

Daniel H. Sterman, MD

RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.

PURPOSE: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.

OBJECTIVES:

* Determine the safety and toxicity of intrapleural BG00001 in patients with malignant pleural mesothelioma or malignant pleural effusions.
* Determine the maximum tolerated dose of this drug in these patients.
* Determine the success of gene transfer/interferon beta gene expression in patients treated with this drug.
* Determine systemic and intrapleural cytokine responses and cellular and humoral immune response in patients treated with this drug.
* Determine, preliminarily, tumor response in patients treated with this drug.

OUTLINE: This is a dose-escalation study.

Patients receive BG00001 via an intrapleural catheter on day 1.

Cohorts of 3-6 patients receive escalating doses of BG00001 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.

Patients are followed weekly for 1 month, biweekly for 1 month, monthly for 4 months, and then every 6 months for 15 years.

PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study.

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies

Abramson Cancer Center at Penn Medicine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer	NCT00003704	Cancer	capecitabine radiation thera...	18 Years -	Alliance for Clinical Trials in Oncology
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00083213	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer	NCT00003704	Cancer	capecitabine radiation thera...	18 Years -	Alliance for Clinical Trials in Oncology
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer	NCT00002506	Cervical Cancer Esophageal Canc... Head and Neck C... Lung Cancer Non-melanomatou... Penile Cancer	recombinant int... isotretinoin	18 Years -	Hoag Memorial Hospital Presbyterian
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	NCT00066404	Cancer	recombinant ade...	18 Years - 120 Years	Abramson Cancer Center at Penn Medicine
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	NCT00066404	Cancer	recombinant ade...	18 Years - 120 Years	Abramson Cancer Center at Penn Medicine
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer	NCT00002506	Cervical Cancer Esophageal Canc... Head and Neck C... Lung Cancer Non-melanomatou... Penile Cancer	recombinant int... isotretinoin	18 Years -	Hoag Memorial Hospital Presbyterian
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer	NCT00003704	Cancer	capecitabine radiation thera...	18 Years -	Alliance for Clinical Trials in Oncology

Spots Global Cancer Trial Database for recurrent penile cancer